A quantitative evaluation of the molecular binding affinity between a monoclonal antibody conjugated to a nanoparticle and an antigen by surface plasmon resonance

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 74, Issue 2, 2010, Pages 148-156

  Debotton, Nir ^a   Zer, Hagit ^a   Parnes, Marcela ^a   Harush Frenkel, Oshrat ^a   Kadouche, Jean ^b   Benita, Simon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MAT Biopharma   (France)

Author keywords

Affinity constant; Cancer; Ferritin; Immunonanoparticles; Monoclonal antibody; Paclitaxel palmitate; Surface plasmon resonance

Indexed keywords

ANTINEOPLASTIC AGENT; FERRITIN; FERRITIN ANTIBODY; H FERRITIN; MALEIMIDE; MONOCLONAL ANTIBODY AMB8LK; MONOCLONAL ANTIBODY AMB8LK PACLITAXEL PALMITATE CONJUGATE; NANOPARTICLE; PACLITAXEL DERIVATIVE; PACLITAXEL PALMITATE; POLYLACTIDE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG PROTEIN BINDING; DRUG SCREENING; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LUNG CARCINOMA; NANOENCAPSULATION; PANCREAS ADENOCARCINOMA; PARTICLE SIZE; QUANTITATIVE ANALYSIS; SURFACE PLASMON RESONANCE;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; APOFERRITINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOTOXINS; KINETICS; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; SURFACE PLASMON RESONANCE;

EID: 75449105002     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.09.014     Document Type: Article

References (54)

1. Olivier J.C., Huertas R., Lee H.J., Calon F., and Pardridge W.M. Synthesis of pegylated immunonanoparticles. Pharmaceutical Research 19 8 (2002) 1137-1143
2. Bourel D., Rolland A., Le Verge R., and Genetet B. A new immunoreagent for cell labeling. CD3 monoclonal antibody covalently coupled to fluorescent polymethacrylic nanoparticles. Journal of Immunological Methods 106 2 (1988) 161-167
3. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Livaniou E., Evangelatos G., and Ithakissios D.S. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. International Journal of Pharmaceutics 259 1-2 (2003) 115-127
4. Tobio M., Sanchez A., Vila A., Soriano I.I., Evora C., Vila-Jato J.L., and Alonso M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids and Surfaces 18 3-4 (2000) 315-323
5. Stolnik S., Dunn S.E., Garnett M.C., Davies M.C., Coombes A.G., Taylor D.C., Irving M.P., Purkiss S.C., Tadros T.F., Davis S.S., et al. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharmaceutical Research 11 12 (1994) 1800-1808
6. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Control Release 70 1-2 (2001) 1-20
7. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews 54 5 (2002) 631-651
8. Fonseca C., Simoes S., and Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. Journal of Control Release 83 2 (2002) 273-286
9. Konan Y.N., Gurny R., and Allemann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. International Journal of Pharmaceutics 233 1-2 (2002) 239-252
10. De Jaeghere F., Allemann E., Leroux J.C., Stevels W., Feijen J., Doelker E., and Gurny R. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharmaceutical Research 16 6 (1999) 859-866
11. Dinauer N., Balthasar S., Weber C., Kreuter J., Langer K., and von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 26 29 (2005) 5898-5906
12. Akasaka Y., Ueda H., Takayama K., Machida Y., and Nagai T. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Design Delivery 3 1 (1988) 85-97
13. Debotton N., Parnes M., Kadouche J., and Benita S. Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles. Journal of Control Release 127 3 (2008) 219-230
14. Torreri P., Ceccarini M., Macioce P., and Petrucci T.C. Biomolecular interactions by surface plasmon resonance technology. Annali dell'Istituto superiore di sanita 41 4 (2005) 437-441
15. Huber W., and Mueller F. Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Current Pharmaceutical Design 12 31 (2006) 3999-4021
16. Van Regenmortel M.H., and Choulier L. Recognition of peptides by antibodies and investigations of affinity using biosensor technology. Combinatorial Chemistry & High Throughput Screening 4 5 (2001) 385-395
17. Johnsson B., Lofas S., and Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Analytical Biochemistry 198 2 (1991) 268-277
18. Johnsson B., Lofas S., Lindquist G., Edstrom A., Muller Hillgren R.M., and Hansson A. Comparison of methods for immobilization to carboxymethyl dextran sensor surfaces by analysis of the specific activity of monoclonal antibodies. Journal of Molecular Recognition 8 1-2 (1995) 125-131
19. Murphy C.J., Gole A.M., Hunyadi S.E., Stone J.W., Sisco P.N., Alkilany A., Kinard B.E., and Hankins P. Chemical sensing and imaging with metallic nanorods. Chemical Communications 5 (2008) 544-557
20. Huang X., Jain P.K., El-Sayed I.H., and El-Sayed M.A. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine 2 5 (2007) 681-693
21. Wang J., and Zhou H.S. Aptamer-based au nanoparticles-enhanced surface plasmon resonance detection of small molecules. Analytical Chemistry 80 18 (2008) 7174-7178
22. Sonvico F., Mornet S., Vasseur S., Dubernet C., Jaillard D., Degrouard J., Hoebeke J., Duguet E., Colombo P., and Couvreur P. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chemistry 16 5 (2005) 1181-1188
23. Laukkanen M.L., Alfthan K., and Keinanen K. Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody. Biochemistry 33 38 (1994) 11664-11670
24. Nielsen U.B., Kirpotin D.B., Pickering E.M., Hong K., Park J.W., Refaat Shalaby M., Shao Y., Benz C.C., and Marks J.D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochimica et Biophysica Acta 1591 1-3 (2002) 109-118
25. Kocbek P., Obermajer N., Cegnar M., Kos J., and Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. Journal of Control Release 120 1-2 (2007) 18-26
26. R.L.J. Kadouche, Use of anti-ferritin monoclonal antibodies in the treatment of some cancers USA Patent 2006.
27. Hazard J.T., and Drysdale J.W. Ferritinaemia in cancer. Nature 265 5596 (1977) 755-756
28. Harrison A., Walker C.A., Parker D., Jankowski K.J., Cox J.P., Craig A.S., Sansom J.M., Beeley N.R., Boyce R.A., Chaplin L., et al. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. International Journal of Radiation Applications and Instrumentation 18 5 (1991) 469-476
29. Camera L., Kinuya S., Garmestani K., Wu C., Brechbiel M.W., Pai L.H., McMurry T.J., Gansow O.A., Pastan I., Paik C.H., et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. Journal of Nuclear Medicine 35 5 (1994) 882-889
30. Guner G., Kirkali G., Yenisey C., and Tore I.R. Cytosol and serum ferritin in breast carcinoma. Cancer Letters 67 2-3 (1992) 103-112
31. Drysdale J.W., Adelman T.G., Arosio P., Casareale D., Fitzpatrick P., Harzard J.T., and Yokota M. Human isoferritins in normal and disease states. Seminars in Hematology 14 1 (1977) 71-88
32. Sabbah E.N., Kadouche J., Ellison D., Finucane C., Decaudin D., and Mather S.J. In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer. Nuclear Medicine and Biology 34 3 (2007) 293-304
33. Decaudin D., Levy R., Lokiec F., Morschhauser F., Djeridane M., Kadouche J., and Pecking A. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody. Anti-cancer Drugs 18 6 (2007) 725-731
34. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., and Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. Journal of Pharmaceutical Sciences 84 4 (1995) 493-498
35. Goldstein D., Gofrit O., Nyska A., and Benita S. Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer. Cancer Research 67 1 (2007) 269-275
36. Harlow E., and Lane D. Antibodies Laboratory Manual (1988), Cold Spring Harbor Laboratory Press, New York
37. Harush-Frenkel O., Debotton N., Benita S., and Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochemical and Biophysical Research Communications 353 1 (2007) 26-32
38. Harush-Frenkel O., Rozentur E., Benita S., and Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9 2 (2008) 435-443
39. BIACORE, Introduction to Kinetic & Affinity Analysis. GE Healthcare, 2008. .
40. Talar-Wojnarowska R., and Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Medical Science Monitor 12 9 (2006) RA186-RA193
41. Espey D.K., Wu X.C., Swan J., Wiggins C., Jim M.A., Ward E., Wingo P.A., Howe H.L., Ries L.A., Miller B.A., Jemal A., Ahmed F., Cobb N., Kaur J.S., and Edwards B.K. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 110 10 (2007) 2119-2152
42. Vriesendorp H.M., and Quadri S.M. Radiolabeled immunoglobulin therapy: old barriers and new opportunities. Expert Review of Anticancer Therapy 1 3 (2001) 461-478
43. Lai J., Quadri S.M., Borchardt P.E., Harris L., Wucher R., Askew E., Schweichel L., and Vriesendorp H.M. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease. Clinical Cancer Research 5 Suppl. 10 (1999) 3315s-3323s
44. Vriesendorp H.M., Quadri S.M., Andersson B.S., Wyllie C.T., and Dicke K.A. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration. Cancer 80 Suppl.12 (1997) 2721-2727
45. Phillips R.J., Mestas J., Gharaee-Kermani M., Burdick M.D., Sica A., Belperio J.A., Keane M.P., and Strieter R.M. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. The Journal of Biological Chemistry 280 23 (2005) 22473-22481
46. McMillian M.K., Grant E.R., Zhong Z., Parker J.B., Li L., Zivin R.A., Burczynski M.E., and Johnson M.D. Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In vitro & Molecular Toxicology 14 3 (2001) 177-190
47. Wustner D., and Faergeman N.J. Chromatic aberration correction and deconvolution for UV sensitive imaging of fluorescent sterols in cytoplasmic lipid droplets. Cytometry A (2008)
48. Blot V., and McGraw T.E. GLUT4 is internalized by a cholesterol-dependent nystatin-sensitive mechanism inhibited by insulin. The EMBO Journal 25 24 (2006) 5648-5658
49. Guyader M., Kiyokawa E., Abrami L., Turelli P., and Trono D. Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. Journal of Virology 76 20 (2002) 10356-10364
50. Thillaivinayagalingam P., Newcombe A.R., O'Donovan K., Francis R., and Keshavarz-Moore E. Detection and quantification of affinity ligand leaching and specific antibody fragment concentration within chromatographic fractions using surface plasmon resonance. Biotechnology and Applied Biochemistry 48 Pt 4 (2007) 179-188
51. Ahmad A., Ramakrishnan A., McLean M.A., and Breau A.P. Use of surface plasmon resonance biosensor technology as a possible alternative to detect differences in binding of enantiomeric drug compounds to immobilized albumins. Biosensors & Bioelectronics 18 4 (2003) 399-404
52. Oddie G.W., Gruen L.C., Odgers G.A., King L.G., and Kortt A.A. Identification and minimization of nonideal binding effects in BIAcore analysis: ferritin/anti-ferritin Fab′ interaction as a model system. Analytical Biochemistry 244 2 (1997) 301-311
53. Velge-Roussel F., Breton P., Guillon X., Lescure F., Bru N., Bout D., and Hoebeke J. Immunochemical characterization of antibody-coated nanoparticles. Experientia 52 8 (1996) 803-806
54. Obermajer N., Kocbek P., Repnik U., Kuznik A., Cegnar M., Kristl J., and Kos J. Immunonanoparticles - an effective tool to impair harmful proteolysis in invasive breast tumor cells. The FEBS Journal 274 17 (2007) 4416-4427